Valion Bio, Inc 8-K, filed Sep 1, 2026
Valion Bio, Inc. (VBIO)
About this 8-K
Valion Bio, Inc filed this 8-K on September 1, 2026, reporting on events of August 27, 2026.
Items reported
- Item 1.01: Entered into a material agreement
- Item 3.02: Unregistered sale of equity
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Building 1, Suite 311 |
||
| (Address of Principal Executive Offices) | (Zip Code) |
| Registrant’s Telephone Number, Including Area Code: |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement.
Valion Bio, Inc., a Delaware corporation (the “Company”) and 3i, LP (“3i”) are parties to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the purchase and sale of (a) up to 8,400 shares of the Company’s Series B Non-Voting Convertible Preferred Stock (“Series B Preferred Shares”) and (b) warrants (“Series B Warrants”) to purchase a number of shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) at an initial exercise price per share determined pursuant to Section 2.2 of the Series B Preferred Purchase Agreement, for an aggregate purchase price of up to $8,400,000 in a series of closings.
The Company, 3i and certain other purchasers are parties to that certain Securities Purchase Agreement, dated as of December 9, 2025 (the “Series C Preferred Purchase Agreement”), with respect to the purchase and sale of (a) up to 75,000 shares of the Company’s Series C Non-Voting Convertible Preferred Stock (“Series C Preferred Shares”) and (b) warrants (“Series C Warrants”) to purchase a number of shares of Common Stock at an initial exercise price per share equal to the Fixed Conversion Price as defined in the Certificate of Designation of Rights and Preferences of the Series C Preferred Shares (the “Series C Certificate of Designation”), for an aggregate purchase price of up to $75,000,000 in a series of closings.
On August 31, 2026, the Company and 3i entered into a letter agreement (the “Letter Agreement”), pursuant to which the Company agreed to issue to 3i (a) 100 Series B Preferred Shares (the “Closing Series B Shares”), (b) Series B Warrants to purchase 3,077 shares of Common Stock at an initial exercise price of $3.62 per share (the “Closing Series B Warrants”), (c) 7,637 Series C Preferred Shares (the “Closing Series C Shares” and, together with the Closing Series B Shares, the “Closing Shares”), and (d) Series C Warrants to purchase 1,053,969 shares of Common Stock for an initial exercise price of $3.62 per share (the “Closing Series C Warrants” and, together with the Closing Series B Warrants, the “Closing Warrants”), for an aggregate purchase price of $7,737,000, to be paid on or about August 31, 2026 (the “Closing Purchase Price” and the closing of such purchase and sale, the “Closing”). The Closing Purchase Price shall consist of (a) $6,137,000 to be retained by 3i to satisfy overdue cash true-up payments pursuant to Section 6(b) of the Series C Certificate of Designation, (b) $100,000 to be retained by 3i to pay the fees of its legal counsel in connection with the purchase of the Company’s securities by 3i and (c) $1,500,000 to be paid to the Company in immediately available funds by wire transfer. The number of shares of Common Stock underlying the Closing Warrants and the exercise price thereof give effect to the Company’s 1-for-25 reverse stock split effective at 12:01 a.m. Eastern Time on August 31, 2026. Such securities were issued under an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506(b) promulgated thereunder. The form of the Letter Agreement is attached to this Current Report as Exhibit 10.1.
Pursuant to the Letter Agreement, the Company also agreed to use its commercially reasonable efforts to (a) file with the Securities and Exchange Commission (the “SEC”), no later than 30 days from the date of the Closing, a registration statement (the “Registration Statement”) covering the maximum number of shares of Common Stock issuable upon conversion of the Closing Shares and the shares of Common Stock issuable upon exercise of the Closing Warrants so as to permit the resale of such securities by 3i, (b) have the Registration Statement declared effective by the SEC no later than 60 days from the date of the Closing, and (c) keep the Registration Statement effective, including but not limited to pursuant to Rule 415 promulgated under the Securities Act of 1933, as amended, and available for the resale by 3i of all of the securities covered thereby at all times until the date on which 3i shall have sold all the securities covered thereby or they cease to require registration pursuant to the Letter Agreement.
| 2 |
Item 3.02 Unregistered Sales of Equity Securities.
The information contained in Item 1.01 is hereby incorporated by reference into this Item 3.02.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Jared Malbin to the Board
On August 27, 2026, the Company appointed Jared Malbin as a member of the board of directors (the “Board”), effective immediately.
Mr. Malbin, 47, has more than 25 years of experience in the financial services industry, spanning broker-dealer operations, compliance, finance and capital markets. Since 2024, Mr. Malbin has served as Chief Operating Officer of Lucid Capital Markets, LLC, a boutique investment banking broker-dealer, where he oversees firm operations and regulatory strategy across the firm’s capital markets and trading businesses. Prior to that, from 2019 to 2024, Mr. Malbin served in senior executive and management roles at investment firms. He has extensive experience building regulatory and compliance functions and guiding firms through regulatory examinations and approval processes. Mr. Malbin also serves on the boards of two private insurance companies. Mr. Malbin holds a Bachelor of Arts degree from Tufts University.
There are no family relationships between Mr. Malbin and any of the Company’s directors, executive officers or persons nominated or chosen by the Company to become a director or executive officer. The Company is not aware of any transactions or relationships between Mr. Malbin and the Company that would require disclosure under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Appointment of Thomas Jensen to the Board
On August 27, 2026, the Company appointed Thomas Jensen as a member of the Board, effective immediately.
Mr. Jensen, 47, has more than 20 years of global biotechnology and oncology experience spanning research and development, corporate strategy and business leadership. Since December 2023, Mr. Jensen has served as Chief Executive Officer of Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage pharmaceutical company, where he oversees the advancement of stenoparib, a dual PARP/WNT inhibitor, through Phase 2 trials in advanced ovarian cancer. Prior to that, Mr. Jensen served as Chief Technology Officer and Head of IT/Investor Relations at Allarity from August 2021 to December 2023. Mr. Jensen currently serves as a director of Allarity and previously served as a director of a Swedish publicly traded investment company. Mr. Jensen holds a Bachelor of Science degree in Biology from the Technical University of Denmark and conducted further studies in Biology at the University of Copenhagen.
There are no family relationships between Mr. Jensen and any of the Company’s directors, executive officers or persons nominated or chosen by the Company to become a director or executive officer. The Company is not aware of any transactions or relationships between Mr. Jensen and the Company that would require disclosure under Item 404(a) of Regulation S-K under the Exchange Act.
| 3 |
Item 7.01 Regulation FD Disclosure.
On September 1, 2026, the Company issued a press release announcing the changes to the Board discussed in Item 5.02 above. A copy of that press release is furnished as Exhibit 99.1 of this Current Report and incorporated herein by reference.
The information set forth under Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 10.1 | Letter Agreement between the Company and 3i, LP, dated August 31, 2026. | |
| 99.1 | Press Release, dated September 1, 2026. | |
| 104 | Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101) |
Forward-Looking Statements
This Current Report contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.
Forward-looking statements in this Current Report or hereafter, including in other publicly available documents filed with the Commission, reports to the stockholders of the Company and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.
| 4 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VALION BIO, INC. | |||
| Date: | September 1, 2026 | By: | /s/ Melinda Lackey |
| Name: Melinda Lackey Title: General Counsel and Senior Vice President of Legal Affairs |
| 5 |
Exhibit 10.1
August 31, 2026
3i, LP
2 Wooster Street, 2nd Floor
New York, NY 10013
Attention: Maier J. Tarlow
| Re: | Side Letter — Closing under Series B Preferred Purchase Agreement and Series C Preferred Purchase Agreement |
Dear Mr. Tarlow:
This letter agreement (this “Letter Agreement”) is entered into as of the date first written above, by and between Valion Bio, Inc., a Delaware corporation (the “Company”), and 3i, LP, a Delaware limited partnership (the “Purchaser”).
The Company and the Purchaser are party to that certain Securities Purchase Agreement, dated April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the purchase and sale of up to 8,400 shares of the Company’s Series B Non-Voting Convertible Preferred Stock (“Series B Preferred Shares”) and warrants (“Series B Warrants”) to purchase a number of shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) at an initial exercise price determined pursuant to Section 2.2 of the Series B Preferred Purchase Agreement, for an aggregate purchase price of up to $8,400,000 in a series of closings. As of the date hereof, the Purchaser has the option, but not the obligation, to purchase up to 1,750 Series B Preferred Shares and corresponding Series B Warrants for up to $1,750,000.
The Company, the Purchaser and certain other purchasers are party to that certain Securities Purchase Agreement, dated as of December 9, 2025 (the “Series C Preferred Purchase Agreement”), with respect to the purchase and sale of (a) up to 75,000 shares of the Company’s Series C Non-Voting Convertible Preferred Stock (“Series C Preferred Shares”) and (b) warrants (“Series C Warrants”) to purchase a number of shares of Common Stock calculated pursuant to Section 2.2 of the Series C Preferred Purchase Agreement at an initial exercise price per share equal to the Fixed Conversion Price as defined in the Certificate of Designation of Rights and Preferences of the Series C Preferred Shares (the “Series C Certificate of Designation”), for an aggregate purchase price of up to $75,000,000 in a series of closings. As of the date hereof, the Purchaser has purchased 6,000 Series C Preferred Shares and corresponding Series C Warrants for an aggregate purchase price of $6,000,000, and has the right, subject to the terms and conditions set forth in the Series C Preferred Purchase Agreement, to purchase up to an additional 31,500 Series C Preferred Shares and corresponding Series C Warrants for an aggregate purchase price of up to $31,500,000.
Capitalized terms not defined herein shall have the meanings assigned thereto in the Series C Preferred Purchase Agreement.
The Company and the Purchaser hereby agree as follows:
1. Closing. The Purchaser agrees, upon the satisfaction of the conditions set forth in Section 2, to purchase from the Company, and the Company agrees to issue to the Purchaser, in a closing (the “Closing”), (a) 100 Series B Preferred Shares (the “Closing Series B Shares”), (b) Series B Warrants to purchase 3,077 shares of Common Stock an initial exercise price of $3.62 per share (the “Closing Series B Warrants”), (c) 7,637 Series C Preferred Shares (the “Closing Series C Shares” and, together with the Closing Series B Shares, the “Closing Shares”), and (d) Series C Warrants to purchase 1,053,969 shares of Common Stock for an initial exercise price of $3.62 per share (the “Closing Series C Warrants” and, together with Closing Series B Warrants, the “Closing Warrants”), for an aggregate purchase price of $7,737,000, to be paid on or about August 31, 2026 (the “Closing Purchase Price”), subject to the satisfaction of each of the conditions set forth in Section 2. The Closing Purchase Price shall consist of (a) $6,137,000 to be retained by the Purchaser to satisfy overdue cash true-up payments pursuant to Section 6(b) of the Series C Certificate of Designation, (b) $100,000 to be retained by the Purchaser to pay the fees of its legal counsel in connection with the purchase of the Company’s securities by the Purchaser and (c) $1,500,000 to be paid to the Company in immediately available funds by wire transfer. The number of shares of Common Stock underlying the Closing Warrants and the exercise price thereof give effect to the Company’s 1-for-25 reverse stock split effective at 12:01 a.m. Eastern Time on August 31, 2026.
| 1 |
2. Closing Conditions. The obligations of the Purchaser hereunder in connection with the Closing are subject to each of the following conditions being satisfied or waived by the Purchaser prior to or at the Closing:
(a) Each of the conditions set forth in Sections 2.3(b) and 2.3(h) of the Series B Preferred Purchase Agreement shall have been satisfied or waived by the Purchaser.
(b) Each of the conditions set forth in Sections 2.3(b) and 2.3(d) of the Series C Preferred Purchase Agreement shall have been satisfied or waived by the Purchaser.
(c) The Purchaser shall have received the Series B Closing Shares and the Series B Closing Warrants.
(d) The Purchaser shall have received the Series C Closing Shares and the Series C Closing Warrants.
(e) The Purchaser shall have received each of the deliverables set forth in Section 2.3(l) of the Series B Preferred Purchase Agreement.
(f) The Purchaser shall have received each of the deliverables set forth in Section 2.3(j) of the Series C Preferred Purchase Agreement.
(g) The Purchaser shall have received appropriate notices from the Company, reasonably satisfactory to the Purchaser, relating to price adjustments in accordance with the terms of the Company’s securities held by the Purchaser after giving effect to the Closing.
(h) The Common Stock is listed on the Nasdaq Capital Market (“Nasdaq”) and the Company is in continued compliance with all of the listing and maintenance requirements of Nasdaq. The Company continues to have no reason to believe that it is not, or with the passage of time will not, be able to comply with its continued listing requirements to remain on Nasdaq.
3. Registration Rights. The Company hereby agrees to use its commercially reasonable efforts to (a) file with the Securities and Exchange Commission (the “SEC”), no later than 30 days from the date of the Closing, a registration statement (the “Registration Statement”) covering the maximum number of shares of Common Stock issuable upon conversion of the Closing Shares and the shares of Common Stock issuable upon exercise of the Closing Warrants so as to permit the resale of such securities by the Purchaser, (b) have the Registration Statement declared effective by the SEC no later than 60 days from the date of the Closing, and (c) keep the Registration Statement effective, including but not limited to pursuant to Rule 415 promulgated under the Securities Act of 1933, as amended, and available for the resale by the Purchaser of all of the securities covered thereby at all times until the date on which the Purchaser shall have sold all the securities covered thereby or they cease to require registration pursuant to this paragraph.
4. Counterparts; Electronic Signatures. This Letter Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which, taken together, shall constitute one and the same instrument. Signatures transmitted by electronic means (including DocuSign or similar electronic signature platforms) shall be deemed original signatures for all purposes.
5. Governing Law. This Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to its conflict of laws principles.
[Signature Page to Follow]
| 2 |
[Signature Page to Side Letter]
Please confirm the Purchaser’s agreement to the foregoing by executing this Letter Agreement in the space provided below.
Very truly yours,
Valion Bio, Inc.
| By: | /s/ Lisa Wolf | |
| Name: | Lisa Wolf | |
| Title: | Chief Operating Officer |
AGREED AND ACCEPTED:
3i, LP
| By: | 3i Management LLC, its General Partner | |
| By: | /s/ Maier J. Tarlow | |
| Name: | Maier J. Tarlow | |
| Title: | Manager |
| 3 |
Exhibit 99.1
FOR IMMEDIATE RELEASE
Valion Bio Announces Changes to Management and Board of Directors
Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.
| · | Lead Asset Positioned for Significant Markets: Entolimod targets the projected $7.8 billion Acute Radiation Syndrome (“ARS”) market by 2032 and a multi-billion-dollar oncology supportive-care opportunity through its differentiated dual-tissue cytoprotection platform¹˒² | |
| · | Focused on Value Creation: Streamlined leadership and additional Board expertise are designed to accelerate execution, strengthen commercial opportunities and better align Valion’s market valuation with the underlying value of its assets, capabilities, and future prospects |
SAN ANTONIO, TX / September 1, 2026 / -- Valion Bio, Inc. (Nasdaq: VBIO) (“Valion” or the “Company”), a clinical-stage biopharmaceutical company, today announced strategic changes to its management team and Board of Directors designed to accelerate execution across its clinical and commercial initiatives and position the Company for its next phase of growth.
The Company’s Board of Directors has unanimously appointed Lisa Wolf to the expanded roles of President and Chief Operating Officer (“COO”), effective immediately. Ms. Wolf will continue to serve as Chief Financial Officer (“CFO”) and will assume executive leadership of the Company following the departure of former Chief Executive Officer, Michael K. Handley.
The expanded role brings Valion’s financial, operational and strategic functions under unified leadership at an important inflection point for the Company. Ms. Wolf will oversee the continued advancement of Valion’s lead product candidate, Entolimod, while directing the Company’s efforts to expand government, international and commercial partnership opportunities.
“Lisa has earned the deep respect and confidence of the Board, and she is uniquely qualified to lead Valion through this next phase of execution and growth,” said Sheryle Bolton, Chair of Valion’s Board of Directors. “Valion has built a differentiated combination of proprietary science, biomanufacturing infrastructure and significant market opportunities. Our priority now is execution — advancing Entolimod, pursuing commercial and government opportunities, and creating a business model capable of generating sustainable value for shareholders.”
“I am energized to assume expanded leadership of Valion at this pivotal stage in the Company’s development,” Ms. Wolf said. “Our objective is clear: translate the potential of Entolimod and our manufacturing platform into meaningful commercial opportunities while maintaining disciplined capital allocation and execution.
Entolimod has the potential to address significant unmet needs across both ARS and oncology supportive care. Its differentiated approach to cytoprotection provides a compelling foundation for pursuing government, institutional and pharmaceutical opportunities.”
| 1 |
Strengthening the Board for Valion’s Next Phase
The Company also announces the recent appointments of Thomas Jensen and Jared Malbin as directors to its Board.
Mr. Malbin brings more than 25 years of financial-services experience spanning broker-dealer operations, compliance, finance and capital markets. He currently serves as Chief Operating Officer of Lucid Capital Markets, LLC, a boutique investment-banking broker-dealer, where he oversees firm operations and regulatory strategy across the firm’s capital-markets and trading businesses. He has extensive experience building regulatory and compliance functions and guiding firms through regulatory examinations and approval processes. Mr. Malbin also serves on the boards of two private insurance companies. He holds a Bachelor of Arts degree from Tufts University.
Mr. Jensen currently serves as Chief Executive Officer, Co-Founder and Director of Nasdaq-listed Allarity Therapeutics. Under his leadership, Allarity is advancing stenoparib, a dual PARP/WNT inhibitor, through Phase 2 trials in advanced ovarian cancer. Mr. Jensen brings more than 20 years of global biotechnology and oncology experience spanning research and development, corporate strategy and business leadership. He holds a Bachelor of Science degree in Biology from the Technical University of Denmark and conducted further studies in Biology at the University of Copenhagen.
“We are very pleased to welcome Jared and Thomas to Valion’s Board,” said Ms. Bolton. “Their combined experience across capital markets, regulatory strategy, biotechnology, oncology and corporate development significantly strengthens the Board as we enter our next phase. These appointments also reflect the importance of maintaining strong alignment among Valion, its Board and its shareholders.”
Sources
1 CoherentMI “Acute Radiation Syndrome Market Size and Share Analysis – Growth Trends and Forecasts” https://www.coherentmi.com/industry-reports/acute-radiation-syndrome-market
2 Market Research.com “Global Chemotherapy-Induced Neutropenia Treatment Market 2026-2035” https://www.marketresearch.com/Orion-Market-Research-v4261/Global-Chemotherapy-Induced-Neutropenia-Treatment-44733511/
About Valion Bio, Inc.
Valion Bio, Inc. (Nasdaq: VBIO) is developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease and immune dysregulation.
The Company’s lead candidate, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome and has been evaluated in animal models under the U.S. Food and Drug Administration’s (“FDA”) Animal Rule, which allows the Agency to approve new drugs and biological products based on animal efficacy studies when human clinical trials are not ethical or feasible, such as in the case of acute radiation exposure. Entolimod is a novel Toll-like Receptor 5 agonist designed to activate NF-κB signaling pathways associated with cellular protection, tissue recovery and immune response. The product candidate has received Fast Track and Orphan Drug designations from the FDA.
Valion Bio is also advancing Entolasta, a next-generation TLR5 agonist designed for potential use in broader therapeutic applications, including oncology supportive care. The Company’s pipeline includes potential programs in neutropenia and immune dysfunction.
For more information, visit www.valionbio.com.
| 2 |
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements.
Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or similar expressions, although not all forward-looking statements contain these words.
Forward-looking statements in this press release include, among others, statements regarding: the development and regulatory advancement of Entolimod under the FDA Animal Rule U.S. or allied-government entities; the timing and outcome of regulatory or government interactions; the potential use of Entolimod before or after radiation exposure; the product candidate’s potential to address gastrointestinal or hematopoietic radiation injury; the initiation, design, timing and outcome of physician-sponsored studies in neutropenia; the development and potential applications of Entolasta; the ability of the Company to expand the TLR5 platform into oncology supportive care or other indications; the scalability, capacity, economics and strategic benefits of the Company’s manufacturing operations; potential third-party CDMO demand or revenue; and the Company’s ability to obtain additional capital and execute its business strategy.
These forward-looking statements are based on Valion Bio’s current expectations, estimates and assumptions and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Actual results could differ materially from those expressed or implied by these forward-looking statements as a result of numerous factors, including the Company’s interactions with and guidance from the FDA and other regulatory authorities; the continued interest of BARDA and other U.S. government agencies in Entolimod; the outcome of the Company’s engagement with Ukraine’s Ministry of Health and other allied governments; whether any Request for Information results in a pre-submission meeting, regulatory authorization, stockpiling agreement, procurement or revenue; the Company’s ability to satisfy the requirements of the FDA Animal Rule; the timing and success of preclinical and clinical studies; the Company’s ability to achieve expected benefits from its development and manufacturing assets; changes in relationships with partners, government agencies or other stakeholders; manufacturing, supply-chain and quality risks; the ability to attract and retain CDMO customers; the Company’s need for and ability to secure additional working capital; the Company’s ability to maintain its Nasdaq listing; changes in tariffs, inflation, political conditions, legal requirements, regulatory policy and economic conditions; and other risks described in the Company’s filings with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on these forward-looking statements. For a discussion of risks and uncertainties relevant to Valion Bio, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, including the section titled “Risk Factors,” as well as the Company’s subsequent filings with the SEC.
Forward-looking statements contained in this press release speak only as of the date of this release. Valion Bio undertakes no obligation to update any forward-looking statement except as required by applicable law.
Investor and Media Contact:
Stephen Kilmer
(646) 274-3580
Stephen.Kilmer@valionbio.com
| 3 |